Improving Efficiency and Reliability of Post-Transplantation Monitoring

This white paper discusses the advancements in monitoring and prognosis of post-transplantation health, specifically focusing on the use of donor-derived cell-free DNA (dd-cfDNA) as a biomarker for assessing graft health. The document outlines the historical context of organ transplantation, emphasizing the need for improved long-term allograft survival and the limitations of traditional monitoring methods such as serum creatinine and urine protein. It details the risks associated with transplantation, including acute and chronic rejection, and the importance of early detection of graft injury. The paper presents dd-cfDNA as a non-invasive alternative to biopsies, highlighting its potential for timely diagnosis of rejection. Various studies are cited to support the effectiveness of dd-cfDNA in predicting graft injury, with findings indicating that it can detect issues earlier than conventional methods. The paper concludes by advocating for the adoption of dd-cfDNA monitoring to enhance patient outcomes and reduce the economic burden associated with transplant complications.